BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim JM, Lee SH, Shin WY, Lee KY, Kim JM, Ahn SI. Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution. ANZ J Surg 2018;88:E840-4. [PMID: 30225975 DOI: 10.1111/ans.14824] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Xing R, Gao J, Cui Q, Wang Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol 2021;12:783236. [PMID: 34899747 DOI: 10.3389/fimmu.2021.783236] [Reference Citation Analysis]
3 Li Q, Xiong DL, Wang H, Jin WL, Ma YY, Fan XM. High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Onco Targets Ther 2021;14:2975-88. [PMID: 33981147 DOI: 10.2147/OTT.S296187] [Reference Citation Analysis]
4 Shetty S, U A, Kumar R, Bharati S. Electrical conductivity spectra of hepatic tumors reflect hepatocellular carcinoma progression in mice. Biomed Phys Eng Express 2020;6. [PMID: 35062002 DOI: 10.1088/2057-1976/abbbd5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 2020;8:e001033. [PMID: 32868393 DOI: 10.1136/jitc-2020-001033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
6 Wang L, Chen Y, Zhang N, Chen W, Zhang Y, Gao R. QIMCMDA: MiRNA-Disease Association Prediction by q-Kernel Information and Matrix Completion. Front Genet 2020;11:594796. [PMID: 33193744 DOI: 10.3389/fgene.2020.594796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, Mukherjee SK, Thursz M, Wong CN, Sharma R, Rimassa L. Immune-based therapies for hepatocellular carcinoma. Oncogene 2020;39:3620-37. [PMID: 32157213 DOI: 10.1038/s41388-020-1249-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
8 Li C, Wang Z, Chen S, Zhang J, Qu K, Liu C. MicroRNA-552 promotes hepatocellular carcinoma progression by downregulating WIF1. Int J Mol Med 2018;42:3309-17. [PMID: 30221686 DOI: 10.3892/ijmm.2018.3882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, Cheng Q, Yang B, Feng X, Lu Y, Xie H, Zhou L, Wu J, Zheng S. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1. Mol Cancer 2020;19:123. [PMID: 32772918 DOI: 10.1186/s12943-020-01239-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 13.5] [Reference Citation Analysis]
10 Bento de Sousa JH, Calil IL, Tustumi F, da Cunha Khalil D, Felga GEG, de Arruda Pecora RA, de Almeida MD. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol. 2021;6:11. [PMID: 33409405 DOI: 10.21037/tgh.2020.01.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tao Y, Wang J, Xu X. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances. Front Bioeng Biotechnol 2020;8:184. [PMID: 32211399 DOI: 10.3389/fbioe.2020.00184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Li H, Luo D, Huttad L, Zhang M, Wang Y, Feng J, Ding Y, Han B. RIPK4 Suppresses the Invasion and Metastasis of Hepatocellular Carcinoma by Inhibiting the Phosphorylation of STAT3. Front Mol Biosci 2021;8:654766. [PMID: 34222329 DOI: 10.3389/fmolb.2021.654766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Young S, Taylor AJ, Sanghvi T. Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. J Clin Transl Hepatol 2018;6:189-97. [PMID: 29951364 DOI: 10.14218/JCTH.2017.00059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
14 Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2021;14:186. [PMID: 35008350 DOI: 10.3390/cancers14010186] [Reference Citation Analysis]
15 Sharma R, Motedayen Aval L. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:652007. [PMID: 33790915 DOI: 10.3389/fimmu.2021.652007] [Reference Citation Analysis]